Skip to main content
. 2007 Mar 20;7:51. doi: 10.1186/1471-2407-7-51

Figure 1.

Figure 1

Kaplan-Meier estimates of progression-free survival (PFS, A) and overall survival (OS, B) for gefitinib-responders. Median PFS was 13.8 months (95% CI = 11.4 to 16.2 months) and median OS was 29.2 months (95% CI = 22.1 to 36.4 months). Bars indicate censored cases.